Yahoo Finance 60 Degrees Pharmaceuticals Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags
60 Degrees Pharmaceuticals (NASDAQ:SXTP) Full Year 2023 Results
Key Financial Results
Net loss: US$3.77m (loss narrowed by 39% from FY 2022).
US$0.95 loss per share (improved from US$2.60 loss in FY 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
60 Degrees Pharmaceuticals Revenues Beat Expectations, EPS Falls Short
Revenue exceeded analyst estimates by 1.4%. Earnings per share (EPS) missed analyst estimates by 11%.
Looking ahead, revenue is forecast to grow 97% p.a. on average during the next 2 years, compared to a 9.0% growth forecast for the Pharmaceuticals industry in the US.
Performance of the American Pharmaceuticals industry.
The company's shares are up 11% from a week ago.
Risk Analysis
It's necessary to consider the ever-present spectre of investment risk. We've identified 6 warning signs with 60 Degrees Pharmaceuticals (at least 5 which are potentially serious), and understanding these should be part of your investment process.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
